drugset / Trial / NCT00867516
Safety, Efficacy and Pharmacokinetics Study of ALD518 in Patients With Active Rheumatoid Arthritis
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The purpose of this study is to determine the safety and efficacy of ALD518 in three different doses in patients who have not had an adequate response to methotrexate.
Timeline
- Start
- 2008-10
- Primary completion
- 2009-06
- Completion
- 2009-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Clazakizumab | Monoclonal antibody | 80 mg | Intravenous |
| Subject | Clazakizumab | Monoclonal antibody | 160 mg | Intravenous |
| Subject | Clazakizumab | Monoclonal antibody | 320 mg | Intravenous |